Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 146,700 shares, a decrease of 14.1% from the February 13th total of 170,700 shares. Based on an average trading volume of 346,000 shares, the short-interest ratio is currently 0.4 days. Currently, 0.9% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI raised its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the quarter. National Bank of Canada FI owned about 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent SEC filing. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Price Performance

NASDAQ SNSE opened at $0.45 on Thursday. The stock’s 50 day simple moving average is $0.48 and its 200-day simple moving average is $0.50. The company has a market cap of $11.32 million, a PE ratio of -0.38 and a beta of 0.16. Sensei Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.94.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a report on Wednesday, January 8th.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.